Barinthus Biotherapeutics (BRNS) Invested Capital (2020 - 2026)

Barinthus Biotherapeutics has reported Invested Capital for 7 years, with the latest figure at $66.4 million in Q1 2026.

• For the quarter ending Q1 2026, Invested Capital fell 42.56% year-over-year to $66.4 million; the trailing twelve-month figure through Mar 2026 stood at $66.4 million (down 42.56% YoY), and the FY2025 full-year result was $74.2 million, down 42.98% from the prior year.
• Invested Capital for Q1 2026 stood at $66.4 million, down from $74.2 million in the prior quarter.
• The five-year high for Invested Capital was $254.8 million in Q2 2022, with the low at $66.4 million in Q1 2026.
• Historically, Invested Capital has averaged $170.0 million across 5 years, with a median of $172.0 million in 2024.
• Annual changes were most pronounced in 2022 — Invested Capital soared 579.14% — and 2025, when it tumbled 46.97%.
• Barinthus Biotherapeutics' Invested Capital stood at $243.2 million in 2022, then decreased by 23.11% to $187.0 million in 2023, then plunged by 30.41% to $130.1 million in 2024, then sank by 42.98% to $74.2 million in 2025, then declined by 10.52% to $66.4 million in 2026.
• The last three Invested Capital figures came in at $66.4 million (Q1 2026), $74.2 million (Q4 2025), and $84.6 million (Q3 2025), per Business Quant data.